Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 17, 2022 1:00pm
181 Views
Post# 34522421

RE:RE:RE:RE:FYI

RE:RE:RE:RE:FYIThey have also assured us that the technicality has been addressed and is no longer an issue. But, that sadly cost us so much - horrible, rushed deal terms and another15 months without any decent analyst coverage. Had the original deal gone through, I suspect the last 15 months would have been far less painful.

Wino115 wrote:

Yes, this was confirmed in our shareholder inquiry call and the initial deal parties included at least 1 US firm.  However, the issue precluding that first deal from going through was described as something purely "technical" which sounded to me like it could have been anything from timing, regulatory issue, deal approval issue, etc...and not a bank turning away.  They were pretty adamant that if they could have gone ahead with the initial underwriting syndicate and the terms worked out they would have, but for the technical glitch that popped up.  So we ended up with an all Canadian syndicate and bought deal with warrants.  

 

qwerty22 wrote: Just to go back to the OO. My memory from Wino is they had an alternate deal lined up before the OO and it fell through. Maybe Wino can confirm that. That sounds like them exactly butting up against this changing sentiment.

It's probably now more important they prove themselves to be a solid, serious company than to pump themselves as the next unicorn. Sounds like the tortoise wins the race atm.

 

 



<< Previous
Bullboard Posts
Next >>